Oxalic Acid

Oxalic Acid

SCHEMBL10317845

NC(=O)CNCc1cccc(-c2ccc(N3CCOCC3)cc2)c1.O=C(O)C(=O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ AOC3 Q16853 11/20 0.59
▸ KDM4E B2RXH2 3/20 0.56
▸ POLB P06746 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.50
▸ SRC P12931 1/20 0.46
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ CTSS P25774 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ JAK2 O60674 1/20 0.42
▸ JAK1 P23458 1/20 0.42
▸ TYK2 P29597 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL10317843 0.83 AOC3 (0.65) AOC3KDM4EPOLBMAPTSRC
Oxalic Acid SCHEMBL10317818 0.79 AOC3 (0.71) AOC3
SCHEMBL11427269 0.79 AOC3 (0.64) AOC3SRCCTSLCTSBCTSS
SCHEMBL12526733 0.77 AOC3 (0.53) AOC3KDM4EMAPTSRCCTSL
SCHEMBL10320682 0.75 AOC3 (0.74) AOC3
Oxalic Acid SCHEMBL10317816 0.74 AOC3 (1.00) AOC3
SCHEMBL3722035 0.74 AOC3 (0.62) AOC3MAPTALDH1A1
SCHEMBL12523755 0.74 AOC3 (0.59) AOC3
SCHEMBL31269911 0.74 AGXT (0.52) AOC3KDM4EPOLBMAPTSMN1; SMN2
SCHEMBL16785090 0.73 AOC3 (0.56) AOC3KDM4EPOLBMAPTSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2479165-B1 GLYCINE COMPOUND ASTELLAS PHARMA INC (JP) 2017-10-25 — — EP disclosed
US-8802679-B2 Glycine compound ASTELLAS PHARMA INC. (JP) 2014-08-12 — — US disclosed
EP-2479165-A1 GLYCINE COMPOUND Astellas Pharma Inc. (JP) 2012-07-25 — — EP disclosed
US-20120184520-A1 GLYCINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184520-A1 GLYCINE COMPOUND SLC5A1, AQP1, VAPB AOC3 894/4885KDM4E 3935/4885POLB 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback